Clinical trials: Antipsychotic Agents
Schizophrenia
SWitching to Abilify Trial (SWAT)
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
- Trial name
- NCT00304616
- Testing
- Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Schizophrenia
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II
The study is a prospective 2 year multimodal follow-up study of initially antipsychotic-naïve first-episode psychotic patients involving a standardized intervention with monotherapy with aripiprazole during the first 6 weeks.
- Trial name
- PECANSII (NCT02339844)
- Testing
- Aripiprazole
- Where
- Denmark
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Schizophrenia, Sensory Gating
Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to…
- Trial name
- NCT00567099
- Testing
- Aripiprzole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New Mexico VA Healthcare System
Schizophrenia, Schizoaffective Disorder
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00535145
- Testing
- Treatment as usual (TAU), Paliperidone ER
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol
Flunarizine is a calcium channel blocker traditionally used for the treatment of vertigo and migraine. It also has the mechanism of action associated with antipsychotic activity (D2 receptor blockade), but has never been tested…
- Trial name
- NCT00740259
- Testing
- Flunarizine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Ambulatório de Bipolaridade
Mania, Schizophrenia
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12…
- Trial name
- UPTAQE (NCT00534222)
- Where
- 6 sites in Netherlands
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Psychotic Disorders
Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for…
- Trial name
- NCT00287027
- Testing
- Risperdal Long Acting Injectable Antipsychotic Medication
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Alliance on Mental Illness New Hampshire
Schizophrenia
Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
The purpose of this study is to investigate the efficacy of flexibly dosed paliperidone extended-release (mechanism to dissolve a drug over time in order to be released slower and steadier into the blood stream) in improving or…
- Trial name
- PASS (NCT00761605)
- Testing
- Paliperidone
- Where
- 8 sites in South Korea
- Volunteers
- 387 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation…
- Trial name
- NCT02469155
- Testing
- ITI-007, Risperidone
- Where
- 11 sites in United States
- Volunteers
- 696 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective
Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With Schizophrenia
The aim of this study is to evaluate the utility of continuous Holter ECG recording with automated, computerized data analysis for measuring antipsychotic-related QTc prolongation during a 24-h period under clinical conditions
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder
- Trial name
- NCT00178958
- Testing
- Holter Monitor
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Schizophrenia, Antipsychotic Drug
Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation
Antipsychotic medications are widely used to treat schizophrenia but may cause constipation, which can lead to abdominal discomfort, reduced quality of life, and poor treatment adherence.
- Trial name
- XQD-AIC (NCT07767526)
- Testing
- Xingqi Daozhi Decoction
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Antipsychotic Induced Weight Gain
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. Furthermore, it is reported significant changes in food intake happened in patients with weight gain after intaking…
- Trial name
- dTMS (NCT07805980)
- Testing
- Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Xiangya Hospital of Central South University
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Schizophrenia, Metabolic Syndrome
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
Schizophrenia and bipolar disorders are major public health problems. The second generation anti-psychotic drugs have efficacy for both positive and negative symptoms and a favorable risk profile as far as movement disorders.
- Conditions
- Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
- Trial name
- NCT02281162
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Psychotic Disorders
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic…
- Trial name
- NCT05633108
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 579,728 people
- Sponsor
- Eisai Co., Ltd.